Business Description
Exicure Inc
NAICS : 325411
SIC : 2834
ISIN : US30205M2008
Description
Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.33 | |||||
| Equity-to-Asset | 0.55 | |||||
| Debt-to-Equity | 0.72 | |||||
| Debt-to-EBITDA | 1.39 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -12.12 | |||||
| Beneish M-Score | 12.65 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 110 | |||||
| 3-Year EPS without NRI Growth Rate | 65.6 | |||||
| 3-Year Book Growth Rate | -52.6 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 24.18 | |||||
| 9-Day RSI | 31.08 | |||||
| 14-Day RSI | 35.84 | |||||
| 6-1 Month Momentum % | 7.63 | |||||
| 12-1 Month Momentum % | -30.02 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.56 | |||||
| Quick Ratio | 2.56 | |||||
| Cash Ratio | 1.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20.1 | |||||
| Shareholder Yield % | 24.09 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | 13.49 | |||||
| Net Margin % | 12.88 | |||||
| FCF Margin % | -93.05 | |||||
| ROE % | 41.75 | |||||
| ROA % | 11.72 | |||||
| ROIC % | 14.46 | |||||
| ROC (Joel Greenblatt) % | 32.68 | |||||
| ROCE % | 20.58 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 0.3 | |||||
| PE Ratio without NRI | 0.31 | |||||
| PS Ratio | 0.11 | |||||
| PB Ratio | 0.45 | |||||
| Price-to-Tangible-Book | 0.46 | |||||
| EV-to-EBIT | 2.74 | |||||
| EV-to-EBITDA | 1.78 | |||||
| EV-to-Revenue | 0.38 | |||||
| EV-to-FCF | -0.41 | |||||
| Price-to-Graham-Number | 0.08 | |||||
| Earnings Yield (Greenblatt) % | 36.51 | |||||
| FCF Yield % | -508.85 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Exicure Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 22.591 | ||
| EPS (TTM) (€) | 1.538 | ||
| Beta | -0.12 | ||
| Volatility % | 97.19 | ||
| 14-Day RSI | 35.84 | ||
| 14-Day ATR (€) | 0.019636 | ||
| 20-Day SMA (€) | 0.5168 | ||
| 12-1 Month Momentum % | -30.02 | ||
| 52-Week Range (€) | 0.323 - 1.3 | ||
| Shares Outstanding (Mil) | 8.65 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Exicure Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Exicure Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Exicure Inc Frequently Asked Questions
What is Exicure Inc(FRA:2H0A)'s stock price today?
The current price of FRA:2H0A is €0.46. The 52 week high of FRA:2H0A is €1.30 and 52 week low is €0.32.
When is next earnings date of Exicure Inc(FRA:2H0A)?
The next earnings date of Exicure Inc(FRA:2H0A) is 2024-07-12 Est..
Does Exicure Inc(FRA:2H0A) pay dividends? If so, how much?
Exicure Inc(FRA:2H0A) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers